Urology PSA Calculator Pro - Prostate Cancer

"Urology app for PSA measurement (eg, density, doubling time) in prostate cancer"

Download now:

"Urology PSA Calculator Pro - Prostate Cancer" is a medical mobile app designed for health practitioner especially in Urology department. "Urology PSA Calculator Pro - Prostate Cancer" app will calculate several measurements regarding prostate specific antigen (PSA). The PSA test is used primarily to screen for prostate cancer. PSA is a protein produced by both cancerous and noncancerous tissue in the prostate. "Urology PSA Calculator Pro - Prostate Cancer" will enable urologist to calculate PSA density (PSAD), PSA doubling time (PSADT), and PSA age volume (PSA-AV).

There are several features of "Urology PSA Calculator Pro - Prostate Cancer", namely:

🔸 Simple and very easy to use app for urologist.

🔸 Precise calculation of PSA density, doubling time, and age volume.

🔸 Useful for management of prostate cancer patient.

🔸 It is totally free. Download now!

Screening for prostate cancer using prostate-specific antigen (PSA) alone leads to unnecessary biopsy and overdiagnosis. PSA density is easily accessible. PSA density was calculated by dividing serum PSA concentration by gland volume. Using a PSA density cutoff of 0.15 as recommended in the literature enhanced specificity but at the cost of missing half of the tumors.

PSA doubling time (PSADT) has been studied as a survival measure in prostate cancer. PSA doubling time, or the change in PSA level over time, has emerged as a useful predictive marker for assessing disease outcome in prostate cancer. PSA doubling time can be an indicator of biochemical and clinical progression of prostate cancer. This "Urology PSA Calculator Pro - Prostate Cancer" app predicts the changes in PSA levels over time.

The PSA-age volume (PSA-AV) score was calculated by multiplying the age and prostate volume and then dividing the total by the prebiopsy PSA level. A PSA-AV score less than 700 had a sensitivity and specificity of 95% and 15%, respectively to predict prostate cancer. The PSA-AV score was more sensitive in younger patients and in patients with a small prostate volume.